In This Section
News Archive

ViperaTAb™

ViperaTAb™ is available in Europe on a named patient basis. ViperaTAb™, a Polyvalent Immune Fab (Ovine), comprises specific antibody fragments that bind and neutralise Vipera berus venom components, including proteases, lipases and cardiotoxins, facilitating their redistribution away from target tissues and subsequent elimination from the body.

ViperaTAb™ is an antidote for the treatment of snakebites by the European common adder (Vipera berus), offering a treatment for the 750 bites which occur each year in Europe*. This product is currently available on a named patient basis in Sweden, Finland, Norway, Denmark, Iceland, Estonia, Latvia, Lithuania and Germany under an agreement with Swedish Orphan Biovitrum International AB (www.sobi.com), and in other territories from Flynn Pharma Limited (www.flynnpharma.com).

ViperaTAb™

Affinity Purified, European Viper Antivenom (Ovine Fab for Injection)

Indication

European common adder (Vipera berus) envenomation

 

 

 

Call us on
+44 (0)1438 727 822
Email Us
office2@flynnpharma.com
Enquire Online
Thank you for letting us use cookies to improve your experience. For more information on the cookies we use see our privacy policy.